Navigation Links
Sangamo BioSciences Reports First Quarter 2012 Financial Results
Date:5/2/2012

the Juvenile Diabetes Research Foundation (JDRF) for activities relating to the completion of our Phase 2b clinical trial of SB-509 in subjects with diabetic neuropathy and funding from CHDI for the development of a ZFP Therapeutic for Huntington's disease.

Research and development expenses were $7.3 million for the first quarter of 2012, compared to $8.3 million for the same period in 2011. The decrease in research and development expenses was primarily due to decreased clinical trial expenses resulting from the completion of our Phase 2b clinical trial of SB-509 and the termination of the program. General and administrative expenses were $3.2 million for the first quarter of 2012, compared to $3.5 million for the same period in 2011.

Total operating expenses for the first quarter of 2012 were $10.5 million, compared to $11.8 million for the same period in 2011.

Recent Highlights

  • Collaboration with Shire to Develop ZFP Therapeutics Aimed at a "Genetic Cure" for Hemophilia and Other Monogenic Diseases. On January 31, 2012, Sangamo entered into a collaboration and license agreement with Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology.  Under the terms of the agreement, the two companies will develop human therapeutic products for seven gene targets, which include blood clotting Factors VII, VIII, IX and X, for treating hemophilia and three additional gene targets to be selected.  Sangamo is responsible for all research activities through the submission of an Investigative New Drug Application (IND) or European Clinical Trial Application (CTA), and Shire will reimburse Sangamo for all internal and external program-related costs.  Shire is responsible for clinical development and commercialization of products generated from the research pro
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
    2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
    3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
    4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
    5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
    6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
    7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
    8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
    9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
    10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
    11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
    (Date:7/30/2014)... JUPITER, Fla. , July 30, 2014 /PRNewswire/ ... global biotechnology company whose patented and proprietary technologies ... enzymes and other proteins for the bioenergy, bio-based ... the appointment of Thomas "Tom" Dubinski as Vice ... responsible for leading the financial and information technology ...
    (Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
    (Date:7/30/2014)... 30, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that their third ... the reduction of recurrence of hypertrophic scars ... initiated. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
    Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
    ... Informed Medical Communications (IMC), a leading provider ... today announced the appointment of Kerry Crawford to ... In this critical role, Kerry will lead operations ... client relationship management systems. This key addition ...
    ... Collexis Holdings Inc.,(OTC Bulletin Board: CLXS), a ... announced today the launch of the world,s first,CTSA ... 38 institutions and,their more than 60,000 life science ... are also winners of the Clinical Translational Science,Awards ...
    ... Denmark, March 3 Following the,completion of the Phase ... Nordic has held an end of Phase,II meeting with ... meeting was,a success and there was an open and ... This meeting represented the first ever formal discussions ...
    Cached Biology Technology:Informed Medical Communications Appoints New Senior Manager, Strategic Operations 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 2Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting 3
    (Date:7/30/2014)... of researchers from the University of Helsinki and the ... reproduce in mice morphological changes which have taken millions ... in the embryonic development of mice teeth, induced in ... very similar to those observed in the fossil registry ... years ago. , To modify the development of ...
    (Date:7/30/2014)... of $1 million from the Cornelia Cogswell Rossi Foundation ... Center. , The newly established Connie Cogswell ... develop a greater breadth and depth of knowledge of ... pace of research to improve human health. , The ... the Laboratory and its external partners, supporting research to ...
    (Date:7/30/2014)... , July 30, 2014 ... mitigation and liveness detection solutions for the biometric ... an industry consortium revolutionizing online authentication with standards ... Mark Cornett , "The decision to join FIDO ... biometric authentication pervasive in use. We believe the ...
    Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2NexID Biometrics Joins the FIDO Alliance 2
    ... of us never considered eating the mud pies we made ... dining on dirt is nothing out of the ordinary. Now ... The Quarterly Review of Biology helps explain why. ... human geophagythe eating of earthis that it protects the stomach ...
    ... a researcher, please contact the Communications and External Relations staff member ... ORNL and its research and development activities, please refer to one ... or comment, you can send it to news@ornl.gov . ... Unsafe commercial motor vehicles may be off the ...
    ... like a computer. An organism,s genome is the software ... do. But instead of electronic circuitry, life relies on ... organisms to function. Now, researchers at the California Institute ... circuit ever created from scratch, made with DNA-based devices ...
    Cached Biology News:Eating dirt can be good for the belly, researchers find 2Eating dirt can be good for the belly, researchers find 3Story tips from the Department of Energy's Oak Ridge National Laboratory, June 2011 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 2Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 3Caltech researchers build largest biochemical circuit out of small synthetic DNA molecules 4
    ... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... MOISTURE. Protein synthesis inhibitor. Inhibits translation ... polypeptide chains. Induces DNA fragmentation in ... cells. Purity: ≥98% by TLC. ...
    ... Stabilizer is a bovine protein-free alternative ... is an aqueous solution that contains ... buffer (3-(N-Morpholino) propanesulfonic acid), pH 6.0 ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
    ... quantitation kit is used to quantitate double-stranded DNA ... RNA or protein. With this kit, DNA is ... detected with a VersaFluor or other fluorometer. The ... ng per ml to 5 micrograms per ml ...
    ... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
    Biology Products: